Home Cart Sign in  
Chemical Structure| 649749-10-0 Chemical Structure| 649749-10-0

Structure of ATN-224
CAS No.: 649749-10-0

Chemical Structure| 649749-10-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ATN-224, a copper-chelator agent, can inhibit intracellular SOD1 with IC50 of 17.5 nM.

Synonyms: Bis(choline)tetrathiomolybdate; ALXN1840; Decuprate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ATN-224

CAS No. :649749-10-0
Formula : C10H28MoN2O2S4
M.W : 432.54
SMILES Code : OCC[N+](C)(C)C.OCC[N+](C)(C)C.[S-][Mo]([S-])(=S)=S
Synonyms :
Bis(choline)tetrathiomolybdate; ALXN1840; Decuprate
MDL No. :MFCD25976790
InChI Key :FSWNJZRQQVVVJT-UHFFFAOYSA-L
Pubchem ID :18442052

Safety of ATN-224

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H460 human NSCLC cells 10 μM 96 hours Induced cell death PMC3871252
KP mouse lung adenocarcinoma cells 5, 10, 15, 20 μM 96 hours Induced cell death PMC3871252
A549 human NSCLC cells 1.25, 2.5, 5, 10, 20 μM 96 hours Induced cell death PMC3871252
A549 human NSCLC cells 10 μM 24 hours Inhibited SOD1 enzyme activity PMC3871252

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Aging model Oral gavage 0.5 mg/kg Daily for 60 days To evaluate the effect of ATN-224 on copper homeostasis, results showed that treatment improved copper homeostasis and preserved ALDH1A1 activity. PMC11842552
Mice KrasG12D Tp53fl/fl mouse model of lung cancer I.p. injections 4 mg/kg Every other day for 4 weeks Reduced tumor burden PMC3871252

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00405574 Prostate Cancer PHASE2 UNKNOWN 2025-09-08 University of California San F... More >>rancisco, San Francisco, California, 94143, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, 21205, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10021, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, 53792, United States Less <<
NCT04594252 Healthy PHASE1 COMPLETED 2020-11-18 Clinical Study Site, London, U... More >>nited Kingdom Less <<
NCT04610580 Healthy PHASE1 COMPLETED 2021-04-26 Nucleus Network Pty Ltd., Melb... More >>ourne, Victoria, 3004, Australia Less <<
NCT04573309 Wilson Disease PHASE2 COMPLETED 2022-06-07 Research Site, New Haven, Conn... More >>ecticut, 06510, United States|Research Site, Grafton, 1010, New Zealand|Research Site, London, SE1 1YR, United Kingdom Less <<
NCT05641311 Wilson Disease PHASE1 COMPLETED 2019-05-02 Richmond Pharmacology Ltd., St... More >> George's University of London, London, United Kingdom Less <<
NCT05686564 Wilson Disease NO_LONGER_AVAILABLE - -
NCT05303324 Healthy PHASE1 COMPLETED 2019-10-09 Clinical Trial Site, London, S... More >>E11YR, United Kingdom Less <<
NCT02273596 Wilson Disease PHASE2 COMPLETED 2018-11-07 Clinical Trial Site, Los Angel... More >>es, California, 90095, United States|Clinical Trial Site, New Haven, Connecticut, 06519, United States|Clinical Trial Site, Chicago, Illinois, 60611, United States|Clinical Trial Site, Ann Arbor, Michigan, 48109, United States|Clinical Trial Site, Vienna, 1090, Austria|Clinical Trial Site, Heidelberg, 69120, Germany|Clinical Trial Site, Warsaw, 02-957, Poland|Clinical Trial Site, Guildford, Surrey, GU27XX, United Kingdom|Clinical Trial Site, Birmingham, B15 2TH, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.56mL

2.31mL

1.16mL

23.12mL

4.62mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories